SCHEMBL4604847

SCHEMBL4604847

Cc1ccccc1NC(=O)Cc1ccc(Oc2cc(C#N)cc(C#N)c2)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.45
P2RX7 Q99572 3/20 0.44
RORC P51449 1/20 0.44
AR P10275 1/20 0.44
ALDH1A1 P00352 6/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
GAA P10253 3/20 0.41
MAPT P10636 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MAPK10 P53779 1/20 0.41
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4602575 0.92 ALDH1A1 (0.46) HPGDSMN1; SMN2RORCARALDH1A1
SCHEMBL2639077 0.92 HPGD (0.47) HPGDSMN1; SMN2P2RX7RORCALDH1A1
SCHEMBL4603118 0.89 MAPT (0.54) HPGDSMN1; SMN2P2RX7RORCALDH1A1
SCHEMBL4603448 0.89 ALDH1A1 (0.47) HPGDSMN1; SMN2P2RX7RORCALDH1A1
SCHEMBL4603769 0.89 ALDH1A1 (0.51) HPGDSMN1; SMN2RORCALDH1A1MEN1
SCHEMBL4603542 0.88 MEN1 (0.53) HPGDSMN1; SMN2RORCALDH1A1MEN1
SCHEMBL4602690 0.87 RORC (0.48) HPGDSMN1; SMN2P2RX7RORCALDH1A1
SCHEMBL4603690 0.87 SMN1; SMN2 (0.48) HPGDSMN1; SMN2RORCALDH1A1MEN1
SCHEMBL13492235 0.86 HPGD (0.47) HPGDSMN1; SMN2P2RX7RORCALDH1A1
SCHEMBL2638619 0.86 ALDH1A1 (0.47) HPGDSMN1; SMN2P2RX7RORCALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940781-A1 PHENYL-ACETAMIDE NNRT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-07-09 EP claimed
WO-2007045573-A1 PHENYL-ACETAMIDE NNRT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-04-26 WO claimed
EP-1940781-A1 PHENYL-ACETAMIDE NNRT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-07-09 EP disclosed
US-7388111-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2008-06-17 US disclosed
WO-2007045573-A1 PHENYL-ACETAMIDE NNRT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-04-26 WO disclosed
US-20070088053-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088053-A1 Non-nucleoside reverse transcriptase inhibitors SAMHD1, QTRT1, RTF1 HPGD 1052/4885SMN1; SMN2 3367/4885P2RX7 2086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.